Claims for Patent: 10,030,061

« Back to Dashboard

Summary for Patent: 10,030,061

Title:	Hepcidin analogues and uses thereof
Abstract:	The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
Inventor(s):	Mark Leslie Smythe, Gregory Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
Assignee:	Protagonist Therapeutics Inc
Application Number:	US15/828,214
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,030,061
Patent Claims:	1. A peptide of formula I: R1—X—Y—R2 (I)(SEQ ID NO:12) or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen, isovaleric acid, isobutyric acid or acetyl; R2 is —NH2 or —OH; X is a peptide sequence having a formula Id: X1-Thr-His-X4-X5-Cys-Ile-X8-Phe-X10 (Id)(SEQ ID NO:24) wherein X1 is Asp, Ida, pGlu, bhAsp or absent; X4 is Phe or Dpa; X5 is Pro or bhPro; X8 is Ile, Lys, Glu, Phe, Gln or Arg; and X10 is Lys or absent; wherein Y is a peptide sequence having a formula IIf: Y1-Pro-Y3-Ser-Y5-Y6-Y7-Y8-Cys-Y10 (IIf)(SEQ ID NO:10) wherein Y1 is Gly, Glu, Val or Lys; Y3 is Arg or Lys; Y5 is Arg or Lys; Y6 is Gly, Ser, Lys, Ile or Arg; Y7 is Trp or absent; Y8 is Val, Thr, Asp, Glu or absent; and Y10 is Lys or absent; wherein the peptide comprises a disulfide bond between the two Cys; wherein said peptide of formula I is optionally PEGylated on R1, X, or Y; wherein a side chain of an amino acid of the peptide is optionally conjugated to a lipophilic substituent or polymeric moiety; and wherein Ida is iminodiacetic acid; pGlu is pyroglutamic acid; bhAsp is β-homoaspartic acid; and bhPro is β-homoproline. 2. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIIFGPRSKGWVCK-NH2 (SEQ ID NO:38). 3. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIIFEPRSKGWVCK-NH2 (SEQ ID NO:128). 4. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCI(K(PEG8))FGPRSKGWVCK-NH2 (SEQ ID NO:172). 5. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKF(K(PEG8))PRSKGWVCK-NH2 (SEQ ID NO:173). 6. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIIFGPRSRGWVC(K(PEG8))-NH2 (SEQ ID NO:201). 7. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCI(K(Palm))FGPRSKGWVCK-NH2 (SEQ ID NO:183). 8. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKF(K(Palm))PRSKGWVCK-NH2 (SEQ ID NO:217). 9. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKFGP(K(Palm))SKGWVCK-NH2 (SEQ ID NO:219). 10. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKFGPRSKGWVC(K(Palm))-NH2 (SEQ ID NO:221). 11. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCI(K(PEG3-Palm))FGPRSKGWVCK-NH2 (SEQ ID NO:222). 12. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKF(K(PEG3-Palm))PRSKGWVCK-NH2 (SEQ ID NO:223). 13. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKFGP(K(PEG3-Palm))SKGWVCK-NH2 (SEQ ID NO:224). 14. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKFGPRS(K(PEG3-Palm))GWVCK-NH2 (SEQ ID NO:225). 15. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKFGPRSKGWVC(K(PEG3-Palm))-NH2 (SEQ ID NO:226). 16. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKFGPRSKGWVC(K(PEG8))-NH2 (SEQ ID NO:176). 17. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCI(K(isoGlu-Palm))FEPRSKGCK-NH2 (SEQ ID NO:241). 18. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKF(K(isoGlu-Palm))PRSKGCK-NH2 (SEQ ID NO:242). 19. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKFEP(K(isoGlu-Palm))SKGCK-NH2 (SEQ ID NO:243). 20. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKFEPRS(K(isoGlu-Palm))GCK-NH2 (SEQ ID NO:244). 21. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCI(K(Dapa-Palm))FEPRSKGCK-NH2 (SEQ ID NO:248). 22. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is: Isovaleric acid-DTHFPCIKFEP(K(Dapa-Palm))SKGCK-NH2 (SEQ ID NO:250). 23. A pharmaceutical composition comprising the peptide or pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutically acceptable carrier or excipient. 24. The peptide or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide is selected from the group consisting of: (a) Isovaleric acid-DTHFPCIKF(K(PEG3-Palm))PRSKGWVCK-NH2 (SEQ ID NO:223); (b) Isovaleric acid-DTHFPCI(K(isoGlu-Palm))FEPRSKGCK-NH2(SEQ ID NO:241); (c) Isovaleric acid-DTHFPCIKF(K(isoGlu-Palm))PRSKGCK-NH2(SEQ ID NO:242); (d) Isovaleric acid-DTHFPCIKFEP(K(isoGlu-Palm))SKGCK-NH2(SEQ ID NO:243); and (e) Isovaleric acid-DTHFPCIKFEPRS(K(isoGlu-Palm))GCK-NH2(SEQ ID NO:244), wherein the amino acids are L-amino acids.